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Abstract
Questions have been raised on the clinical value of the metabolic syndrome (MS). The negative 
opinion regarding MS is anchored basically on a separate analysis of 4 conditions: obesity, 
dyslipidemia, hypertension and glucose intolerance. The common denominator of these 4 sets 
of arguments is that they represent an utterly simplistic view of MS as a solely predictive tool 
of morbidity or mortality. We believe that it is inequitable to compare it with statistically con-
structed predictive tools, including stronger prognostic variables even unrelated to one another 
from the biological point of view. Several recent large meta-analyses — one of them including 
nearly one million patients — systematically showed that people with MS are at increased risk 
of cardiovascular (CV) events. MS was associated with a 2-fold increase in CV outcomes and 
a 1.5-fold increase in all-cause mortality rates. A very important finding was that CV risk 
still remained high in patients with MS but without diabetes. The presence of MS possesses  
a definitely predictive value, but above all it is a widely accepted concept regarding a biological 
condition based on complex and interrelated pathophysiological mechanisms emanating from 
excess central adiposity and insulin resistance. The risk factors are multiplicative, meaning 
that the risk of a CV disease from risk factors rises geometrically, not linearly, as the number 
of risk factors increases. Therefore, currently available evidences strongly support the concept 
of the MS as a critical clustering of CV risk factors and diabetes, representing a true and solid 
evolving clinical entity. (Cardiol J 2014; 21, 1: 1–5)
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Introduction
During the last few years, an enormous 
amount of articles have been published regarding 
a relatively new diagnostic category: the metabolic 
syndrome (MS). These articles have proliferated 
in medical literature in the fields of internal me-
dicine, cardiology, endocrinology, metabolism, 
hypertension and related disciplines. Initially, in 
1988 Reaven [1] proposed a conceptual framework 
which linked several apparently unrelated biologi-
cal events into a single pathophysiological assem-
ble. His hypothesis argued that insulin resistance 
triggered a common mechanism underlying the 
associated abnormalities of blood pressure, high 
density lipoprotein cholesterol (HDL-C), trigly-
cerides (TG) and glucose tolerance. This concept 
subsequently evolved to encompass a number of 
multiple definitions [2] established by the World 
Health Organization (WHO) [3], the National 
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Cholesterol Education Program Adult Treatment 
Panel III (ATP III) [4], the European Group for 
the Study of Insulin Resistance [5] and the Inter-
national Diabetes Federation (IDF) [6]. Central 
obesity has been added to the above mentioned risk 
factors, which were ranked in different pathogenic 
priorities and with dissimilar cut-off points for the 
individual risk factors [7]. More recently, the IDF 
and the modified ATP III definitions have become 
more concordant, with the remaining difference 
pertaining to waist measurement [8].
However, questions have been raised concer-
ning the clinical value of the MS [9]. Perhaps the 
most direct assault on the theory has been issued 
in a joint report [10] from the American Diabetes 
Association (ADA) and the European Association 
for the Study of Diabetes (EASD), which questions 
the very existence of MS. In sharp contrast, a joint 
position paper from the American Heart Asso-
ciation and the National Heart, Lung, and Blood 
Institute, firmly defends the concept [11].
In the present review we deal with the pros 
and cons of this issue. We will firstly briefly de-
scribe the main arguments against the survival of 
MS as an independent clinical entity. Then, we are 
going to offer the current evidence to the contrary, 
in an attempt to cut the Gordian knot around the 
MS entanglement.
Cons
The negative opinion regarding the syndro-
me is anchored on the analysis of 4 conditions: 
obesity, dyslipidemia, hypertension and glucose 
intolerance.
First, regarding obesity it may be argued that 
excess adiposity is not a consequence of insulin 
resistance, but a change that increases the like-
lihood that an individual will be insulin resistant. 
In addition, not all obese individuals are insulin 
resistant [12] and, as a corollary, the risk factors for 
cardiovascular disease (CVD) should be confined to 
the subset of obese individuals who are also insulin 
resistant [13]. Obesity, per se, in the absence of 
the metabolic characteristics of insulin resistance, 
should not increase the incidence of either CVD or 
type 2 diabetes mellitus (T2DM) [14].
Second, there is a highly significant relation-
ship between insulin resistance, compensatory 
hyperinsulinemia, and hypertriglyceridemia [15], 
which is not limited to an increase in plasma TG 
concentrations. Thus, although various definitions 
of MS have selected the combination of a high 
plasma TG and a low HDL-C concentration as 
diagnostic criteria, these changes are also asso-
ciated with a decrease in low-density lipoprotein 
(LDL) and the postprandial accumulation of TG- 
-rich remnant lipoproteins [16]. Both high TG and 
low HDL-C have been shown to increase risk of 
CVD [17] and may develop for reasons other than 
insulin resistance/hyperinsulinemia.
Third, essential hypertension is intimately lin-
ked to insulin resistance/hyperinsulinemia. Firstly, 
as a group, patients with essential hypertension are 
insulin resistant and hyperinsulinemic [18]. Secon-
dly, normotensive first-degree relatives of patients 
with essential hypertension are relatively insulin 
resistant and hyperinsulinemic as compared to 
a matched control group without a family history 
of hypertension [19]. Thirdly, hyperinsulinemia, as 
a surrogate estimate of insulin resistance, has been 
shown in population-based studies to predict the 
eventual development of essential hypertension 
[20]. These data provide substantial support for 
the theory that insulin resistance/hyperinsulinemia 
plays a role in the pathogenesis of essential hyper-
tension [9]. On the other hand, probably no more 
than 50% of patients with essential hypertension 
are insulin resistant [21]. However, it is only this 
subset of patients that display the components of 
the various definitions of MS that render them at 
greatest risk for CVD [9].
Fourth, it is well established that prevalence 
of some degree of abnormal glucose tolerance 
and/or T2DM is the abnormality most closely 
related to insulin resistance. More than 70 years 
ago Himsworth and Kerr presented evidence that 
“a state of diabetes might result from inefficient 
action of insulin as well as from a lack of insulin” 
[22]. Nowadays it is quite clear that resistance 
to insulin-mediated glucose disposal is present 
in great majority of individuals with T2DM [23], 
and that insulin resistance (or hyperinsulinemia 
as a surrogate estimate of insulin resistance) is 
a powerful and independent predictor of the deve-
lopment of T2DM [24].
Therefore, taking into consideration the 4 cla-
ims, the criteria for the syndrome will encompass 
individuals with overt disease (like CVD, T2DM, 
hypertension), as well as with far milder forms of 
the same conditions. The definition will capture 
a spectrum of severities, and it is highly likely that 
a person who satisfies the diagnostic criteria with 
risk factor levels just over the cut point will have 
a much lower CVD risk than another individual 
with the same combination but higher risk factor 
levels [10].
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Pros
The common denominator of the above men-
tioned 4 sets of arguments is that they represent an 
utterly simplistic view of MS as a solely predictive 
tool of morbidity or mortality [25]. Of course, the 
presence of MS possesses a definite predictive 
value, but first of all it is a widely accepted con-
cept regarding a biological condition based on the 
complex and interrelated pathophysiological me-
chanisms emanating from excess central adiposity 
and insulin resistance. Therefore, it is inequitable 
to compare it with statistically constructed predic-
tive tools, including stronger prognostic variables 
even unrelated to one another from the biological 
point of view. For example, in the criteria for MS 
(in contrast to Framingham score) age and LDL 
cholesterol (LDL-C) levels are not included, as 
well as a variety of strong predictors used in other 
risk stratification scores: previous myocardial 
infarction, heart failure, smoking, family history, 
etc. However, MS identifies additional important 
residual vascular risk mainly associated with insu-
lin resistance and atherogenic dyslipidemia (low 
HDL-C, high TG, small dense LDL-C). Therefore, 
MS could be a useful additional tool in estimation of 
global cardiovascular (CV) risk beyond age, gender, 
high LDL-C or other standard risk factors.
Additionally, one of the important questions 
still remaining open is its predictive value: does 
MS forecast CV events, diabetes onset or disease 
progression any better than the sum of its compo-
nents? For the time being, the strongest available 
evidence points toward a positive answer [25]. 
Three consecutive large meta-analyses syste-
matically showed that people with MS are at 
increased risk of CV events [26–28]. The most 
recent and largest of them [28] included nearly 
1 million patients (total n = 951,083). There, the 
investigators concluded that MS is associated with 
a 2-fold increase in CV outcomes and a 1.5-fold 
increase in all-cause mortality rates. That meta-
-analysis showed that the point estimates for CV 
risk were consistently higher in women than in 
men. In addition, a very important finding of this 
study demonstrated that CV risk was still high in 
patients with MS but without diabetes. Moreover, 
it was demonstrated that the syndrome predicts CV 
events or/and diabetes independently from other 
conventional risk factors [29, 30]. Our group has 
shown that MS is a strong independent predictor 
of mortality and morbidity in patients with acute 
coronary syndrome [30]. It should be specifically 
pointed out that our patients with hyperglycemia 
and MS had higher mortality rates compared with 
patients with the same hyperglycemia but without 
MS (for example 30-day mortality rates respecti-
vely 8.3% vs. 2.5%, p < 0.05).
Analyzing the progression of carotid athero-
sclerosis, it should be stressed that subjects with 
MS have higher levels of intima–media thickness 
(IMT) and total plaque area at follow up than those 
without MS. MS predicts progression of IMT in in-
dividuals below 50 years of age, but not in older age 
groups, suggesting thus that MS may be involved in 
the initial steps of the atherosclerotic process [31].
Another argument in favor of the biological 
soundness of MS is based on experimental rese-
arch. For instance, it should be noted that GLUT4 
expression, accompanied by whole-body insulin 
resistance and increased plasma concentration of 
inflammatory biomarkers was found in an animal 
model of MS [32], similarly, it has been observed 
in humans.
Even critics of the MS concept should agree 
that obesity, dysglycemia, dyslipidemia and hyper-
tension coexist more frequently than predicted by 
mere chance. These common chronic conditions 
(and components of MS) have partially overlap-
ping mechanisms of pathogenic actions mediated 
through common metabolic pathways. Therefore, 
their total combined effect could be less than the 
sum of the individual effects [25].
Emerging varied areas of current MS research 
interests include heterogeneous topics like adipo-
nectin and biomarkers preserving endothelial he-
alth [33, 34], angiotensinogen, resistin, and leptin 
secretion [33], nonalcoholic fatty liver disease and 
liver steatosis [35], hyperuricemia [36], genetic 
predisposition [37], the role of adypocytokines and 
neurohumoral dysregulation [38]; sleep disorders 
and ethnicity [39], the possible ways for treatment 
optimization in patients with CVD [40]. Additional 
related matters are currently investigated, like heart 
rate (HR) turbulence; it has been shown that this 
turbulence — a well-established predictor of cardiac 
autonomic dysfunction — is significantly impaired 
in MS patients without T2DM in adults [41]. Re-
garding childhood and adolescence, HR variability 
is disturbed in children [42], and several equations 
have been developed in order to early identify and 
adequately treat MS in young populations, taking 
into consideration racial, ethnic and gender diffe-
rences [43]. A multimarker approach to MS could 
further improve CV risk stratification [44].
The concept that the MS is a consequence of 
obesity and insulin resistance, provides a useful 
“life-style changes” approach for prevention and 
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treatment: caloric restriction, weight-loss and 
increased physical activity. The next step could 
theoretically be pharmacological interventions 
such as metformin, acarbose, fibrates, weight-loss 
drugs (like orlistat) and perhaps glucagon-like 
peptide-1 agonists [45] or eventual new drugs to 
simultaneously treat several risk factors. A third 
step is represented by the surgical approach. 
A recent study authored by Rizzello et al. [46] and 
performed according to the updated guidelines 
for meta-analyses of non-randomized studies [47] 
depicts several promising surgical approaches for 
MS, including adjustable silicone gastric banding, 
Roux-en-Y gastric bypass, biliopancreatic diversion 
and bariatric surgery.
Conclusions
Currently available evidences strongly support 
the concept of MS as very far of being factitious. 
Quite the opposite, it is a critical clustering of CV 
risk factors and diabetes, representing a true and 
solid evolving clinical entity. These risk factors are 
multiplicative, meaning that the risk for CVD from 
risk factors rises geometrically, not linearly, as the 
number of risk factors increases. Therefore, the 
total risk that MS represents is much more than 
a mere summation of the isolated factors [48, 49]. 
MS is a multifactorial syndrome, standing firstly on 
2 tightly intertwined conditions: obesity and insu-
lin resistance; obesity causes insulin resistance, 
and on the other hand, insulin resistance modifies 
adipose tissue responses to insulin and thereby 
recapitulates the obese state. This situation is 
exacerbated by the concomitant factors [11, 48]. 
MS prevention, recognition, treatment, and better 
understanding of its underlying mechanisms should 
become an important approach for the reduction 
of CVD burden in the general population. Future 
problem-oriented research is needed to improve 
and unify its diagnostic criteria, its genetic and 
environmental basis and the optimal medical ma-
nagement.
Acknowledgements
This work was supported in part by the 
Cardiovascular Diabetology Research Foundation 
(RA 58-040-684-1), Holon, Israel.
Conflict of interest: none declared
References 
 1.  Reaven GM. Banting Lecture 1988. Role of insulin resistance in 
human disease. Diabetes, 1988; 37:1595–1607.
 2.  Simmons RK, Alberti KG, Gale EA et al. The metabolic syndro-
me: Useful concept or clinical tool? Report of a WHO Expert 
Consultation. Diabetologia, 2010; 53: 600–605. 
 3.  World Health Organization. Definition, diagnosis and classifica-
tion of diabetes mellitus and its complications. Part 1: Diagnosis 
and classification of diabetes mellitus. WHO, Geneva, Switzer-
land, 1999, pp. 1–59.
 4.  Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of meta-
bolic syndrome: Report of the National Heart, Lung, and Blood 
Institute/American Heart Association conference on scientific 
issues related to definition. Circulation, 2004; 109:433–438.
 5.  Balkau B, Charles MA. Comment on the provisional report from 
the WHO consultation. European Group for the Study of Insulin 
Resistance (EGIR). Diabet Med, 1999; 16: 442–443.
 6.  Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: A new 
worldwide definition. Lancet, 2005; 366:1059–1062.
 7.  Lee IT, Chiu YF, Hwu CM et al. Central obesity is important but 
not essential component of the metabolicsyndrome for predicting 
diabetes mellitus in a hypertensive family-based cohort. Results 
from the Stanford Asia-pacific program for hypertension and in-
sulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc 
Diabetol, 2012; 11: 43.
 8.  Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the meta-
bolic syndrome. A Joint Interim Statement of the International 
Diabetes Federation Task Force on Epidemiology and Preven-
tion; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atheroscle-
rosis Society; and International Association for the Study of 
Obesity. Circulation, 2009; 120: 1640–1645.
 9  Reaven GM, The individual components of the metabolic syndro-
me: is there a raison d’etre? J Am Coll Nutr, 2007; 26: 191–195.
 10.  Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: 
time for a critical appraisal. Joint statement from the American 
Diabetes Association and the European Association for the Study 
of Diabetes. Diabetes Care, 2005; 28: 2289–2304.
 11.  Grundy SM, Cleeman JI, Daniels SR et al. American Heart As-
sociation; National Heart, Lung, and Blood Institute: Diagnosis 
and management of the metabolic syndrome: An American Heart 
Association/ National Heart, Lung, and Blood Institute Scientific 
Statement. Circulation, 2005; 112: 2735–2752.
 12.  Abbasi F, Brown BWB, Lamendola C, McLaughlin T, Reaven GM. 
Relationship between obesity, insulin resistance, and coronary 
heart disease. J Am Coll Cardiol, 2002; 40: 937–943.
 13.  McLaughlin T, Abbasi F, Lamendola C et al. Differentiation be-
tween obesity and insulin resistance in the association with 
C-reactive protein. Circulation, 2002; 106: 2908–2912.
 14.  Meigs JB, Wilson PWF, Fox CS et al. Body mass index, metabolic 
syndrome, and risk of type 2 diabetes or cardiovascular disease. 
J Clin Endocrinol Metab, 2006; 91: 2906–2912.
 15.  Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of 
insulin in hypertriglyceridemia. Am J Med, 1974; 57: 551–560.
 16.  Jeppesen J, Hollenbeck CB, Zhou M-Y et al. Relation between 
insulin resistance, hyperinsulinemia, postheparin plasma lipo-
protein lipase activity, and postprandial lipemia. Arterioscler 
Thromb Vasc Biol, 1995; 15: 320–324.
 17.  Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. 
HDLs and alimentary lipemia: studies in men with previous 
myocardial infarction at young age. Arterioscler Thromb, 1993; 
13: 11–22.
 18.  Swislocki ALM, Hoffman BB, Reaven GM, Insulin resistance, 
glucose intolerance and hyperinsulinemia in patients with hy-
pertension. Am J Hypertens, 1989; 2: 419–423.
www.cardiologyjournal.org 5
Enrique Z. Fisman, Alexander Tenenbaum, The metabolic syndrome entanglement: Cutting the Gordian knot
 19.  Allemann Y, Horber FF, Colombo M et al. Insulin sensitivity and 
body fat distribution in normotensive offspring of hypertensive 
parents. Lancet, 1993; 341: 327–331.
 20.  Taittonen L, Uhari M, Nuutinen M, Turtinen J, Pokka T, Åkerblom HK. 
Insulin and blood pressure among healthy children. Am 
J Hypertens, 1996; 9:193–199.
 21.  Zavaroni I, Mazza S, Dall’Aglio E, Gasparini P, Passeri M, Reaven GM. 
Prevalence of hyperinsulinaemia in patients with high blood 
pressure. J Intern Med, 1992; 231: 235–240.
 22.  Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive 
types of diabetes mellitus. Clin Sci, 1939; 4: 119–152.
 23.  Reaven GM. Insulin resistance in non-insulin-dependent diabetes 
mellitus. Does it exist and can it be measured? Am J Med, 1983; 
74: 3–17.
 24.  Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin 
secretory dysfunction as precursors of non-insulindependent 
diabetes mellitus. N Engl J Med, 1993; 329: 1988–1992.
 25.  Tenenbaum A, Fisman EZ. “The metabolic syndrome... is dead”: 
These reports are an exaggeration. Cardiovasc Diabetol, 2011; 
10: 11.
 26.  Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk 
of incident cardiovascular events and death: a systematic review 
and meta-analysis of longitudinal studies. J Am Coll Cardiol, 
2007; 49: 403–414.
 27.  Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardio-
vascular disease: A meta-analysis. Am J Med, 2006; 119: 812–819.
 28.  Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and 
cardiovascular risk. A systematic review and meta-analysis. J Am 
Coll Cardiol, 2010; 56: 1113–1132.
 29.  Dohi T, Miyauchi K, Kasai T et al. Impact of metabolic syndrome 
on 10-year clinical outcomes among patients with acute coronary 
syndrome. Circ J, 2009; 73: 1454–1458.
 30.  Feinberg MS, Schwartz R, Tanne D et al. Impact of the metabolic 
syndrome on the clinical outcomes of non-clinically diagnosed 
diabetic patients with acute coronary syndrome. Am J Cardiol, 
2007; 99: 667–672.
 31.  Herder M, Arntzen KA, Johnsen SH, Mathiesen EB. The meta-
bolic syndrome and progression of carotid atherosclerosis over 
13 years. The Tromso study. Cardiovasc Diabetol, 2012; 11: 77.
 32.  Leguisamo NM, Lehnen AM, Machado UF et al. GLUT4 content 
decreases along with insulin resistance and high levels of inflam-
matory markers in rats with metabolic syndrome. Cardiovasc 
Diabetol, 2012; 11: 100. 
 33.  Hiuge A, Tenenbaum A, Maeda N et al. Effects of peroxisome 
proliferator-activated receptor ligands, bezafibrate and fenofi-
brate, on adiponectin level. Arterioscler Thromb Vasc Biol, 2007; 
27: 635–641.
 34.  Ramli J, Calderon Artero P, Block RC, Mousa SA. Novel thera-
peutic targets for preserving a healthy endothelium: Strategies 
for reducing the risk of vascular and cardiovascular disease. 
Cardiol J, 2011; 18: 352–363. 
 35.  Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty 
liver disease and cardiovascular disease: epidemiological, clini-
cal and pathophysiological evidences. Intern Emerg Med, 2012; 
7 (suppl. 3): 291–296. 
 36.  Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as 
a factor in the metabolic syndrome. Curr Hypertens Rep, 2010; 
12: 113–119.
 37.  Garaulet M, Madrid JA. Chronobiology, genetics and metabolic 
syndrome. Curr Opin Lipidol, 2009; 20: 127–134.
 38.  Kong AP, Chan NN, Chan JC. The role of adipocytokines and neu-
rohormonal dysregulation in metabolic syndrome. Curr Diabetes 
Rev, 2006; 2: 397–407.
 39.  Brady EM, Davies MJ, Hall AP, Talbot DC, Dick JL, Khunti K. 
An investigation into the relationship between sleep-disordered 
breathing, the metabolic syndrome, cardiovascular risk profiles, 
and inflammation between South Asians and Caucasians residing 
in the United Kingdom. Metab Syndr Relat Disord, 2012; 10: 
152–158. 
 40.  Tenenbaum A, Motro M, Fisman EZ et al. Bezafibrate for the 
secondary prevention of myocardial infarction in patients with 
metabolic syndrome. Arch Intern Med, 2005; 165: 1154–1160.
 41.  Erdem A, Uenishi M, Kukukdurmaz Z et al. The effect of meta-
bolic syndrome on heart rate turbulence in non-diabetic patients. 
Cardiol J, 2012; 19: 507–512.
 42.  Altuncu ME, Baspinar O, Keskin M. The use of short-term analy-
sis of heart rate variability to assess autonomic function in obese 
children and its relationship with metabolic syndrome. Cardiol J, 
2012; 19: 501–506.
 43.  Gurka MJ, Ice CL, Sun SS, Deboer MD. A confirmatory factor 
analysis of the metabolic syndrome in adolescents: An exami-
nation of sex and racial/ethnic differences. Cardiovasc Diabetol, 
2012; 11: 128. 
 44.  Rasouli M, Nesarhosseini V Kiasari AM et al. The multiplicative 
interactions of leukocyte counts with some other risk factors 
enhance the prognostic value for coronary artery disease. Cardiol 
J, 2011; 8: 246–253.
 45.  Sullivan SD, Ratner RE. Should the metabolic syndrome patient 
with prediabetes be offered pharmacotherapy? Curr Diab Rep, 
2011; 11: 91–98.
 46.  Rizzello M, De Angelis F, Campanile FC, Silecchia G. Effect of 
gastrointestinal surgical manipulation on metabolic syndrome: 
a focus on metabolic surgery. Gastroenterol Res Pract, 2012; 
2012: 670418. doi: 10.1155/2012/670418. Epub 2012 Oct 22.
 47.  Navarese EP, Koziński M, Pafundi T et al. Practical and updated 
guidelines on performing meta-analyses of non-randomized stu-
dies in interventional cardiology. Cardiol J, 2011; 18: 3–7. 
 48.  Grundy SM. Does the metabolic syndrome exist? Diabetes Care, 
2006; 29: 1689–1692.
 49.  Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of 
myocardial infarction in 27,000 participants from 52 countries: 
A case-control study. Lancet, 2005; 366: 1640–1649. 
